费斯治疗
FTH
18.80
-1.80
-8.74%
费斯治疗
US · FTH
#3576 按市值排名
上市于 2021
18.80
-1.80
-8.74%
实时 - 追踪5344个代码 - 心跳于484秒前
· 2026-10-16 19:30
✦ 量化股权信号 计算方式说明
涨跌不一/平稳
- 机构持股总比例基本持平。
机构持股
- 机构持股比例
- 66.02% -0.02pp
- 机构数量
- 51
- 数据截至
- 2026/Q3 较上一报告期
持股变动 vs 资金流向
方向分歧机构在上一报告期减持了股份，同时该股在最近20个交易日的主力资金呈净流入——两者方向出现分歧。
机构持股变动数据按季度发布且存在滞后；资金流向数据为每日更新。请将其作为方向性的交叉验证参考，而非精确的择时信号。
持股人类型
Hedge Fund45.40%
VC/PE Fund17.42%
Individual/Insider4.27%
Mutual Fund2.15%
Private Company0.67%
Family Office/Trust0.31%
Other29.72%
主要股东 截至 2026-06-15
Khosla Ventures, LLC
10.19% · 2.63M 股
Montanova Capital, LLC
7.82% · 2.02M 股
Avoro Capital Advisors LLC
5.59% · 1.44M 股
Baker Bros. Advisors LP
4.98% · 1.29M 股
Balyasny Asset Management L.P.
4.03% · 1.04M 股
Cormorant Asset Management, LP
3.98% · 1.03M 股
Anand Parikh
3.16% · 817.70K 股
RA Capital Management, L.P.
2.79% · 722.02K 股
Fairmount Funds Management LLC
2.79% · 722.02K 股
Logos Global Management, L.P.
2.79% · 722.02K 股
条形长度是相对于此处列出的最大股东而言，并非相对于公司100%股权。
内部人持股
共追踪50份申报 · 24次买入 · 16次卖出
| 姓名 | 职务 | 持股比例 |
|---|---|---|
| Khosla Ventures, LLC | -- | 10.19% |
| Anand Parikh | Chief Operating Officer | 3.16% |
| James Peyer | Independent Director | 0.50% |
| Brian Stephenson | Chief Financial Officer | 0.18% |
| Stephen Hahn | Director | 0.17% |
| Karen Vousden | Scientific Co-Founder | 0.16% |
| Thomas Ricks | Independent Director | 0.07% |
| Robert Holmen | Independent Director | 0.00% |
| John Celebi | Chief Executive Officer | 0.00% |
| Christopher Gerry | General Counsel | 0.00% |
内部人交易 最近的 Form 4 申报记录
| 日期 | 姓名 | 职务 | 类型 | 股数 | 价格 |
|---|---|---|---|---|---|
| 2026-09-10 | Karen Vousden | Scientific Co-Founder | Other Derivative Acquisition | +25,000 | $37.44 |
| 2026-09-10 | Karen Vousden | Scientific Co-Founder | Initial Statement of Beneficial | 0 | -- |
| 2026-07-21 | Cambrian BioPharma, Inc. | -- | Intent to Sell (Form 144) | -130,142 | $27.99 |
| 2026-07-20 | Anand Parikh | Chief Operating Officer | Other Derivative Acquisition | +398,018 | $28.37 |
| 2026-07-20 | Josiah Craver | Officer | Other Derivative Acquisition | +30,824 | $28.37 |
| 2026-06-30 | Brian Stephenson | Chief Financial Officer | Open Market Acquisition | +13,634 | $22.95–24.98 |
| 2026-06-25 | Brian Stephenson | Chief Financial Officer | Open Market Acquisition | +15,641 | $23.61–27.77 |
| 2026-06-22 | Brian Stephenson | Chief Financial Officer | Open Market Acquisition | +17,413 | $20.23–25.91 |
| 2026-06-21 | Anand Parikh | Chief Operating Officer | Open Market Acquisition | +2,806 | $19.76 |
| 2026-06-21 | Anand Parikh | Chief Operating Officer | Derivative Exercise and Retained | +53,465 | $1.16 |
| 2026-06-14 | Khosla Ventures, LLC | -- | Initial Statement of Beneficial | 0 | -- |
| 2026-06-14 | Stephen Hahn | Director | Derivative Exercise and Retained | +44,763 | -- |
| 2026-06-14 | Anand Parikh | Chief Operating Officer | Derivative Exercise and Retained | +761,428 | -- |
| 2026-06-12 | Brian Stephenson | Chief Financial Officer | Initial Statement of Beneficial | 0 | -- |
| 2026-06-11 | Sona Saira Ramasastry | Director | Other Derivative Acquisition | +25,000 | $13.00 |
| 2026-06-11 | Sona Saira Ramasastry | Director | Initial Statement of Beneficial | 0 | -- |
| 2026-06-11 | Stephen Hahn | Director | Other Derivative Acquisition | +25,000 | $13.00 |
| 2026-06-11 | Stephen Hahn | Director | Initial Statement of Beneficial | 0 | -- |
| 2026-06-09 | Robert Holmen | Independent Director | Other Derivative Acquisition | +12,500 | $11.41 |
| 2026-06-09 | Phillip Donenberg | Director | Other Derivative Acquisition | +12,500 | $11.41 |
Form 4 申报记录，每家公司显示最新的一批。"Other Derivative Acquisition"（其他衍生品获取）类目多为限制性股票/期权归属，并非公开市场买入——具体类型见"类型"列。
报价时间 2026-10-16 19:30:04 · 仅供参考，不构成投资建议，也未考虑您的具体情况。
费斯治疗 讨论区 0 条评论